Home Danaher Reports Second Quarter 2025 Financial Results with Net Earnings of $555 Million and 1.5% Core Revenue Growth

Danaher Reports Second Quarter 2025 Financial Results with Net Earnings of $555 Million and 1.5% Core Revenue Growth

Jul 23, 2025 17:52 CST Updated 17:52
Danaher

Product Design and Manufacturer

Image


Danaher announced its second-quarter financial results for the period ending June 27, 2025, on July 22 local time.


Key Financial Data for Q2 2025:

• Net income was $555 million, or $0.77 diluted earnings per share; adjusted net diluted earnings per share under non-GAAP was $1.80.

• Revenue increased by 3.5% year-over-year, reaching $5.9 billion; core revenue under non-GAAP grew by 1.5% year-over-year.

• Operating cash flow was $1.3 billion, and free cash flow under non-GAAP was $1.1 billion.


"Our performance this quarter exceeded expectations, thanks to the outstanding execution by our team leveraging the Danaher Business System, as well as the continued strong growth and highly disciplined cost control within our Bioprocessing business," said Rainer M. Blair, President and Chief Executive Officer of the company.


He further pointed out, "Despite the continued uncertainty in the macro environment, we believe that with a talented team, a differentiated portfolio, and a solid financial foundation, the company will be well-positioned to continue creating long-term value for shareholders for the remainder of 2025 and beyond."


Q3 2025 and Full-Year Outlook:

Regarding future core sales growth and adjusted diluted net earnings per share, the company does not reconcile these non-GAAP metrics with their respective GAAP (Generally Accepted Accounting Principles) measures. This is because, apart from an anticipated $1.7 billion in annual amortization of acquisition-related intangible assets in 2025 and an expected favorable currency impact of 1.5% for Q3 2025 and 1.0% for the full year, other factors that could affect GAAP results—such as exchange rate fluctuations, mergers and acquisitions, divestitures, tax adjustments, asset impairments, investment gains or losses—are difficult to predict and are often influenced by uncontrollable events. These factors may have a significant impact on GAAP results.


• For the third quarter of 2025, the company expects core revenue to achieve a year-over-year "low single-digit growth."


• For the full year 2025, the company maintains its expectation of approximately 3% year-over-year growth in core revenue. Meanwhile, the company has raised its full-year guidance range for adjusted diluted net earnings per share from the previous $7.60 to $7.75, to $7.70 to $7.80.


Brief Analysis of Danaher's Q2 Earnings Report:

Business Trends and Industry Impact


1. Core Driver —— Bioprocessing Business Continues to Gain Momentum

Danaher CEO Clearly Points Out: The Bioprocessing Sector Continues to Achieve Strong Growth This Quarter, Becoming the Key Engine Driving Overall Revenue. This Means:


☞Post-epidemic recovery of the pharmaceutical and bioproducts industry chain is evident
☞ The assets acquired by Danaher, such as Cytiva and Pall, are delivering synergistic benefits.
☞ Against the backdrop of still-strong global biopharmaceutical investments, Danaher's bioprocessing business may continue to outperform its peers.


2. Robust Cost Control, High Profit Quality

Adjusted EPS reached $1.80, surpassing market expectations, thanks to the continuous optimization of operational efficiency driven by the "Danaher Business System (DBS)," demonstrating Danaher's outstanding lean management capabilities amidst global economic uncertainties.


3. The macro environment is "fluid," but remains resilient.

Management acknowledges the significant fluctuations in the macro environment but has not lowered its full-year forecast. Instead, it has slightly raised its profit target, demonstrating a certain level of confidence in the second-half business performance—possibly suggesting:

☞The demand structure is becoming stable after the pandemic.
☞Global hospital capital procurement is recovering, especially in the fields of life science and diagnostic equipment.


4. Enlightenment to the Industry

☞ M&A integration strategy remains effective: Danaher's recent divestiture/acquisition strategies (such as the Vontier spin-off) have enabled it to focus more on high value-added areas, which may serve as a reference for other IVD giants.
☞The upturn in bioprocessing activity has been confirmed, and suppliers of biopharmaceutical equipment and raw materials both in China and abroad are expected to benefit simultaneously.
☞Ample free cash flow provides sufficient ammunition for future capital allocation (re-acquisitions, buybacks, etc.).

-END-

Source: Danaher

Editor: Xue Mo
Review: Xianyu
Editor: Mu Linsen

Submission Email:tougao@caivd-org.cn


Image

Featured Recommendations


The 22nd China International Laboratory Medicine and Blood Transfusion Instrument Reagent Expo (CACLP) Grandly Opens!

The 12th China In Vitro Diagnostics Industry Development Conference (CAIVD)
"The 10th China Experimental Medicine Conference 'Voice of Innovation' Grandly Held in Hangzhou"
The 5th China In Vitro Diagnostics Key Raw Materials and Components Forum Successfully Held
Bright•Test —— The 8th In Vitro Diagnostics Young Entrepreneurs Forum Successfully Convened
Gathering New Momentum | The 7th China IVD Distribution Enterprises Forum Successfully Convened

Setting Sail | The First China IVD Enterprises Globalization Overseas Forum Successfully Convened

The First National Grassroots Medical Testing Forum Successfully Held
The First Human-to-Animal Medical Device Forum Successfully Held
The First AI and Digital Twin Technology Academic Salon Successfully Held
① The final interpretation rights and copyrights of the original content published by this official account belong to ZhiAo RuiHe (Shanghai) Exhibition Co., Ltd. For reprinting, please indicate the source as "CACLP In Vitro Diagnostics Information" at the beginning of the article, and enter "reprint" in the information column to obtain reprint guidelines. ② Articles cited from other sources in this official account are reprinted and do not represent the views or positions of this platform. ③ Media cooperation: 021-52258212

Image

Image

Image

Image